2026 Artemetrx State of Specialty Spend and Trend Report Webinar

July 23 | 12:00pm CT

PSG announces the results of the industry’s go-to report on specialty drug spend and trend.

With specialty drug costs remaining a top concern and a pipeline bursting with breakthrough therapies, payers can’t afford to manage specialty spend with yesterday’s strategies. The 2026 Artemetrx State of Specialty Spend and Trend Report delivers the critical data needed to stay ahead of the curve.

Join our industry experts as they unveil the trends reshaping specialty drug management today. Leveraging real-world pharmacy and medical claims data from our book of business, this webinar is your roadmap to proactive specialty spend control.

Key Findings

• Specialty Drug Trend: Specialty drug trend continues in the low double digits
• Claim Utilization: Claim utilization is now the dominant driver of specialty drug trend as more members use specialty drugs
• Top Specialty Drugs by Spend: Major shifts are occurring in the ranking of top specialty drugs by spend
• Biosimilar Market Share: Biosimilars market share is growing rapidly as Humira and Stelara biosimilars gain traction

Expert insight from our panelists:

Renee Rayburg, RPh

Vice President, Clinical Strategy

Kelly Dean, MBA

Vice President, Analytics

Morgan Lee, PhD, MPH, CPH

Vice President, Research & Marketing